Abstract
Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Current Cancer Therapy Reviews
Title: Update on the Rheumatologic Manifestations of Malignancy
Volume: 3 Issue: 3
Author(s): Lianne Marks, Clifton D. Fuller, Parag Sanghvi, Melva Pinn and Charles R. Thomas
Affiliation:
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Abstract: Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Export Options
About this article
Cite this article as:
Lianne Marks , Clifton D. Fuller , Parag Sanghvi , Melva Pinn and Charles R. Thomas , Update on the Rheumatologic Manifestations of Malignancy, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368378
DOI https://dx.doi.org/10.2174/157339407781368378 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pulmonary Manifestations of Rheumatoid Arthritis, Psoriatic Arthritis and Peripheral Spondyloarthritis: Prevalence, Diagnostic Approach and Treatment Options
Current Rheumatology Reviews Chymase Inhibitors
Current Pharmaceutical Design Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology The Two Faces of Interleukin-17A in Atherosclerosis
Current Drug Targets Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) COX-2 Inhibitors and Cardiovascular Events: Deja Vu Du Jour
Vascular Disease Prevention (Discontinued) Acute Severe Colitis: Infliximab and/or Cyclosporine?
Current Drug Targets The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Mining PeptideAtlas for Biomarkers and Therapeutics in Human Disease
Current Pharmaceutical Design Assorted Applications of N-substituted-2,4-thiazolidinediones in Various Pathological Conditions
Mini-Reviews in Medicinal Chemistry Methotrexate Hepatotoxicity in Children with Juvenile Idiopathic Arthritis: A Single-Center Study
Current Rheumatology Reviews Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Biomarker Approach Towards Rheumatoid Arthritis Treatment
Current Rheumatology Reviews Formulation and in-vitro Evaluation of a Bilayer Matrix Tablet Containing Aceclofenac as Sustained Release and Paracetamol as Immediate Release
Drug Delivery Letters Essential Polymers Helping Patients with Obesity
Current Applied Polymer Science MicroRNA-16-5p Controls Development of Osteoarthritis by Targeting SMAD3 in Chondrocytes
Current Pharmaceutical Design IRAK-4 Inhibitors for Inflammation
Current Topics in Medicinal Chemistry Current Anti-Inflammatory Therapies and the Potential of Secretory Phospholipase A2 Inhibitors in the Design of New Anti-Inflammatory Drugs: A Review of 2012 - 2018
Current Medicinal Chemistry Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology